Bioatla (BCAB) Investor presentation summary

Leadership and platform overview

• Experienced leadership and scientific advisory team with backgrounds in major biotech and pharma companies.

• CAB (Conditionally Active Biologics) platform leverages tumor acidity for selective antibody binding, enhancing safety and efficacy.

• CAB technology enables reversible, tumor-specific binding, avoiding off-tumor toxicity and widening the therapeutic index.

• Broad applicability across antibody formats, including ADCs, bispecific TCEs, CAR-Ts, and other proteins.

Pipeline and clinical programs

• Diverse pipeline targeting multiple solid tumors, including advanced programs for EpCAM, ROR2, AXL, and CTLA-4.

• BA3182 (EpCAM x CD3 DualCAB TCE) shows manageable safety and preliminary antitumor activity in advanced adenocarcinomas, with ongoing dose escalation.

• Ozuriftamab Vedotin (CAB-ROR2-ADC) demonstrates clinical responses and improved survival in HPV+ OPSCC, with pivotal trial design agreed upon with FDA.

• Mecbotamab Vedotin (CAB-AXL-ADC) shows promising survival and response rates in mKRAS NSCLC and soft tissue sarcoma, with potential for pan-mKRAS strategy.

• Evalstotug (CAB-CTLA-4) achieves high response rates and reduced immune-mediated adverse events in melanoma and other solid tumors, especially in combination with PD-1 inhibitors.

Clinical and preclinical evidence

• CAB antibodies demonstrate improved selectivity and safety in preclinical models, with up to 100-fold improvement in therapeutic index.

• Clinical data show durable responses and manageable safety profiles across multiple tumor types and heavily pretreated populations.

• BA3182 achieves objective tumor reductions and prolonged disease control at higher doses, with transient, manageable hepatic analyte elevations.

• Ozuriftamab Vedotin achieves 42% ORR and 11.6 months median OS in HPV+ OPSCC, outperforming standard of care in cross-trial comparisons.

• Mecbotamab Vedotin yields 31% ORR and 67% one-year survival in mKRAS NSCLC, with activity across multiple KRAS variants.

• Evalstotug in combination with PD-1 shows up to 62% ORR in first-line melanoma and 54% ORR in previously treated patients, with lower rates of severe immune-related AEs compared to ipilimumab.